US Patent 10899833 Human antibody specific for interleukin-1 alpha
Patent 10899833 was granted and assigned to Janssen Biotech on January, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 17 Oct, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 21 Mar, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+292 characters)
Article
Patent abstract
Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 25 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
108998330
Date of Patent
January 26, 2021
0Patent Application Number
157897740
Date Filed
October 20, 2017
0Official Website
Patent Primary Examiner
Edits on 27 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
108998330
Date of Patent
January 26, 2021
0Patent Application Number
157897740
Date Filed
October 20, 2017
0Official Website
Patent Primary Examiner
Edits on 17 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 9 Feb, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10899833 Human antibody specific for interleukin-1 alpha
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10899833
Date of patent
January 26, 2021
Patent application number
15789774
Date Filed
October 20, 2017
Patent primary examiner
Find more entities like US Patent 10899833 Human antibody specific for interleukin-1 alpha
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
